IndraLab

Statements

KRAS increases the amount of JOSD2. 1 / 1

| 1

reach

"By comparing the clinical tumor samples from KRAS-mutant/wild-type CRC patients, in addition to integrating oncogenic mutations (G12C, G12D, G12V, G12A, G12S, G13C, G13D, G13V) into KRAS wild-type cells, our study substantiated the hypothesis that the mutational activation of KRAS robustly augments JOSD2 expression."

40240366

INDRA sources:

Colored badges next to statement headings correspond to evidence counts from knowledge sources, as shown below. Badges to the left of the | separator correspond to curated knowledge base sources, and badges to the right of it correspond to machine reading systems.

IndraLab

Statements

KRAS increases the amount of JOSD2. 1 / 1

INDRA sources:

Databases

Reading